{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:01:22Z","timestamp":1793703682851,"version":"4.5.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1053\/j.gastro.2013.05.048","type":"journal-article","created":{"date-parts":[[2013,6,2]],"date-time":"2013-06-02T12:02:09Z","timestamp":1370174529000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":811,"title":["Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis"],"prefix":"10.1053","volume":"146","author":[{"given":"William J.","family":"Sandborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewel","family":"Johanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omoniyi J.","family":"Adedokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"J\u00e4rnerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2013.05.048_bib1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.05.048_bib2","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.05.048_bib3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2013.05.048_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.05.048_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"10.1053\/j.gastro.2013.05.048_bib6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2013.05.048_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","article-title":"Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study","volume":"69","author":"Keystone","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2013.05.048_bib8","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2013.05.048_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.05.048_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2013.05.048_bib11","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2013.05.048_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. a randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2013.05.048_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A\u00a0review of activity indices and efficacy endpoints for clinical trials of medical therapy in\u00a0adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.05.048_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.05.048_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clinthera.2011.11.015","article-title":"Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study","volume":"34","author":"Zhuang","year":"2012","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2013.05.048_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-\u03b1 monoclonal antibody, in\u00a0subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1053\/j.gastro.2013.05.048_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"key":"10.1053\/j.gastro.2013.05.048_bib18","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"Suppl S1","key":"10.1053\/j.gastro.2013.05.048_bib19","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/00054725-201212001-00063","article-title":"Clinical response is a meaningful endpoint in ulcerative colitis clinical studies","volume":"18","author":"Sandborn","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2013.05.048_bib20","article-title":"Practical nonparametric statistics","author":"Conover","year":"1980","journal-title":"Hoboken: John Wiley & Sons, Inc"},{"key":"10.1053\/j.gastro.2013.05.048_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.gastro.2006.12.037","article-title":"A\u00a0meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis","volume":"132","author":"Su","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.05.048_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/216847900604000412","article-title":"Adaptive seamless Phase II\/III designs\u2014background, operational aspects, and examples","volume":"40","author":"Maca","year":"2006","journal-title":"Drug Inf"},{"key":"10.1053\/j.gastro.2013.05.048_bib23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508513008469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508513008469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:06:40Z","timestamp":1758035200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508513008469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0016508513008469"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2013.05.048","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2013.05.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2013.06.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}